ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Ambys Medicines forms to tackle liver diseases

by Lisa M. Jarvis
August 18, 2018 | APPEARED IN VOLUME 96, ISSUE 33

 

Third Rock Ventures and Takeda Pharmaceutical have put up $60 million to launch Ambys Medicines, a biotech firm that is developing regenerative medicines for liver diseases. Ambys also signed a partnership with Takeda worth another $80 million. Ambys is pursuing three treatment types: gene therapy to revive liver function, cellular therapy to replace damaged liver cells, and small molecules to restore the function of key proteins. The company’s scientific founders includes University of Illinois, Urbana-Champaign, chemist Martin Burke, who previously founded Revolution Medicines.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment